AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.ygyno.2025.04.579
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0090825825008054
其他信息:
出版社: Elsevier BV
作者: Jung-Yun Lee; Sathana Boonyapipat; Guangwen Yuan; Hee Seung Kim; Jeong-Won Lee; Li Wang; Tao Wang; Danbo Wang; Desheng Yao; Hu Liu; Chih-Long Chang; Timur Turdeevich Andabekov; Xiang Zhang; Wei Wang; Yong Man Kim; Ivan Volodymyrovych Sinielnikov; Kai Wang; Yujuan Gao; Xiyan Mu; Lingying Wu